Ongoing Clinical Trials for Threatened Abortion
Currently, there is 1 ongoing clinical trial investigating treatment options for threatened abortion (also known as: threatened miscarriage). This trial is focused on using a combination of antibiotics to help prevent late pregnancy loss and improve outcomes for babies at risk.
Clinical trial locations
Study on Antibiotic Combination of Ceftriaxone, Clarithromycin, and Metronidazole for Pregnant Women with Threatened Miscarriage and Intact Membranes
This clinical trial is designed to help pregnant women who are experiencing signs of a late miscarriage, specifically between 18 and 24 weeks of pregnancy. The study focuses on cases where the protective membranes around the baby are still intact, meaning the water has not broken yet.
Who can participate:
- Pregnant women carrying a single baby (not twins or multiples)
- Pregnancy between 18 weeks and 23 weeks and 6 days
- Signs of threatened late miscarriage, identified by an ultrasound showing a cervix that is 10 millimeters or less, or the amniotic sac protruding during examination
- The baby must be alive at the time of enrollment
- Age 18 years or older
- No regular and painful uterine contractions
- Able to understand French language instructions
- Affiliated with social security
Who cannot participate:
- Women who are not pregnant
- Women not experiencing a threatened late miscarriage
- Women with broken membranes
- Women not hospitalized for this condition
- Women pregnant with multiple babies
- Men
What the trial aims to do:
The main goal of this study is to extend the pregnancy as long as possible and improve the health outcomes for babies at risk of being born too early. By preventing early delivery, the trial aims to reduce the risk of death and serious health problems in newborns, including lung disorders, infections, brain bleeding, and intestinal complications that can affect premature babies.
Investigational medications:
The trial tests a combination of three antibiotics:
- Ceftriaxone – given as an injection
- Clarithromycin – taken as a 500 mg tablet by mouth
- Metronidazole – taken as a 500 mg tablet by mouth
These antibiotics are commonly used to treat infections and may help prevent complications that could lead to miscarriage or affect the baby’s health. Participants will be randomly assigned to receive either the antibiotic combination or a placebo, and both mother and baby will be monitored throughout the pregnancy and after birth. The study is expected to continue until March 2028.
Summary
Currently, research into treatments for threatened abortion is limited, with only one ongoing trial identified. This trial is being conducted in France and focuses specifically on late threatened miscarriage occurring between 18 and 24 weeks of pregnancy. The study takes an innovative approach by investigating whether a combination of antibiotics can help prevent pregnancy loss and improve newborn health outcomes.
The trial concentrates on a specific subset of patients: those with intact membranes and ultrasound findings indicating high risk for late miscarriage. By targeting bacterial infections that may contribute to pregnancy complications, researchers hope to extend pregnancies and reduce serious health problems in premature babies.
The limited number of trials in this area highlights the need for further research into effective interventions for threatened abortion, particularly in the late second trimester when the risks to both mother and baby can be significant.